TScan Therapeutics’ (TCRX) “Buy” Rating Reiterated at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $11.00 target price on the stock. Needham & Company LLC’s target price would suggest a potential upside of 107.94% from the stock’s previous close.

A number of other brokerages have also recently commented on TCRX. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics presently has an average rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Trading Up 4.1 %

Shares of TCRX opened at $5.29 on Wednesday. TScan Therapeutics has a fifty-two week low of $3.73 and a fifty-two week high of $9.69. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. The company’s fifty day moving average is $5.35 and its 200 day moving average is $6.60. The stock has a market capitalization of $280.21 million, a PE ratio of -5.04 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. Sell-side analysts expect that TScan Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was acquired at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $221,200. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was purchased at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the purchase, the director now owns 40,000 shares of the company’s stock, valued at $221,200. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 15,000 shares of company stock valued at $82,550 in the last quarter. 2.76% of the stock is owned by insiders.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds have recently made changes to their positions in the company. abrdn plc raised its holdings in shares of TScan Therapeutics by 27.2% in the third quarter. abrdn plc now owns 371,655 shares of the company’s stock valued at $1,851,000 after acquiring an additional 79,511 shares in the last quarter. SG Americas Securities LLC purchased a new position in TScan Therapeutics during the 3rd quarter valued at about $78,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $90,000. Troluce Capital Advisors LLC bought a new position in shares of TScan Therapeutics during the second quarter valued at approximately $543,000. Finally, Great Point Partners LLC purchased a new position in TScan Therapeutics during the second quarter valued at approximately $5,504,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.